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ARTICLE
TNF blockade induces a dysregulated type I
interferon response without autoimmunity in
paradoxical psoriasis
Curdin Conrad1, Jeremy Di Domizio 1, Alessio Mylonas1, Cyrine Belkhodja1, Olivier Demaria1,
Alexander A. Navarini2, Anne-Karine Lapointe1, Lars E. French2, Maxime Vernez1 & Michel Gilliet1
Although anti-tumor necrosis factor (TNF) agents are highly effective in the treatment of
psoriasis, 2–5% of treated patients develop psoriasis-like skin lesions called paradoxical
psoriasis. The pathogenesis of this side effect and its distinction from classical psoriasis
remain unknown. Here we show that skin lesions from patients with paradoxical psoriasis are
characterized by a selective overexpression of type I interferons, dermal accumulation of
plasmacytoid dendritic cells (pDC), and reduced T-cell numbers, when compared to classical
psoriasis. Anti-TNF treatment prolongs type I interferon production by pDCs through inhi-
bition of their maturation. The resulting type I interferon overexpression is responsible for the
skin phenotype of paradoxical psoriasis, which, unlike classical psoriasis, is independent of
T cells. These ﬁndings indicate that paradoxical psoriasis represents an ongoing overactive
innate inﬂammatory process, driven by pDC-derived type I interferon that does not lead to T-
cell autoimmunity.
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Tumor necrosis factor (TNF) is a homotrimeric cytokineproduced by immune and epithelial cells in response toinfection or tissue injury1,2. TNF exerts potent pro-
inﬂammatory functions via activation of immune cells and vas-
cular endothelial cells2–4. Increased TNF expression levels can be
found at sites of inﬂammation in many autoimmune diseases,
such as rheumatoid arthritis, Crohn’s disease, or psoriasis5–7.
TNF blockade is highly efﬁcacious and has become the bench-
mark in management of these diseases8–11. As such, more than
two million patients have been treated with TNF blockers.
Nevertheless, TNF blockade as a therapeutic option has its lim-
itations. Long-term TNF neutralization increases susceptibility to
infections and skin cancer12,13. Another common side effect of TNF
blockade is the development of inﬂammatory skin lesions, which
resemble psoriasis and are observed in 2–5% of patients receiving
anti-TNF therapy14–18. These skin manifestations are called “para-
doxical psoriasis”, as TNF blockade is usually highly efﬁcacious in
psoriasis treatment. Notably, this side effect even occurs in patients
undergoing successful psoriasis treatment with anti-TNFs. More
severe cases necessitate interruption or complete cessation of anti-
TNF therapy and, for several diseases, no equivalent alternative
treatments exist. Therefore, understanding the pathogenic mechan-
ism underlying paradoxical psoriasis, and its distinctions from
classical psoriasis, remains a critical issue for the future design of
successful therapeutic and preventive measures.
Classical psoriasis is a chronic, autoimmune skin disease mediated
by T cells19–21. Evidence for a pathogenic role of T cells stems from
the following observations: ﬁrst, T-cell-targeted therapies, including
cyclosporine (inhibition of calcineurin in activated T cells), DAB-IL-
2 (interleukin-2 receptor-speciﬁc fusion toxin)22, and inhibitors of
T-cell costimulation, including alefacept23, efalizumab24, and CTLA-
4-Ig25, are efﬁcacious in psoriasis treatment; second, HLA-Cw6
represents the strongest genetic risk variant associated with psor-
iasis26; third, clinically relevant xenotransplant models of psoriasis
are dependent on T cells27–29; and, ﬁnally, lesional T cells are oli-
goclonal and recognize epidermal autoantigens30–34. These patho-
genic T cells mediate the chronic and relapsing course of psoriasis
and deﬁne it as an autoimmune disease.
Autoimmune T-cell responses in psoriasis are initiated by a
subset of dendritic cells called plasmacytoid dendritic cells
(pDCs), which inﬁltrate pre-psoriatic skin and are activated to
produce type I interferons (IFNs)35. pDC-derived type I IFNs
unleash the autoimmune response by promoting activation and
maturation of conventional DCs (cDCs) that stimulate expansion
of autoreactive T cells. These autoreactive T cells—in particular
CD8+ T cells—migrate into the epidermis, where they recognize
keratinocyte autoantigens and induce keratinocyte hyperproli-
feration28,36. Whether paradoxical psoriasis follows a similar
pathomechanism remains unknown.
Here we show that paradoxical psoriasis induced by anti-TNF
is characterized by an exaggerated type I IFN response, which
does not lead to T-cell autoimmunity. Anti-TNF antibodies
directly increase the capacity of pDCs to produce type I IFNs, by
inhibiting their maturation. The exaggerated type I IFN response
induced by anti-TNF treatments is sufﬁcient to trigger a psoriatic
skin phenotype. However, in contrast to classical psoriasis, type I
IFN fails to induce cDC maturation and the subsequent activation
of autoimmune T cells that is required for a chronic-relapsing
disease course. Thus, paradoxical psoriasis is a side effect of an
anti-TNF treatment stemming from an overactive, but self-
limiting innate inﬂammation driven by pDC-derived type I IFN.
Results
Clinical characterization of paradoxical psoriasis. We analyzed
25 paradoxical psoriasis patients as summarized in
Supplementary Table 1. Mean age of the patients was 44.8 years
(range 15–73 years). Mean duration of anti-TNF treatment until
onset of paradoxical psoriasis was 9.5 months (range 3 weeks to 5
years). Anti-TNF therapy indications include Crohn’s disease (n
= 6), psoriasis and/or psoriatic arthritis (n = 8), ankylosing
spondylitis (n = 8), rheumatoid arthritis (n = 1), as well as SAPHO
(n = 1) and juvenile rheumatoid arthritis (n = 1). Patients were
treated with the anti-TNF antibodies inﬂiximab (n = 10), adali-
mumab (n = 10), certolizumab (n = 1), and golimumab (n = 2),
and the TNF-receptor fusion protein etanercept (n = 2). Anti-
TNF-induced paradoxical psoriasis appeared independent of the
underlying diseases or the type of anti-TNF agent used (Sup-
plementary Table 1). Paradoxical psoriasis regressed in all
patients when anti-TNF therapy was discontinued, but relapsed
or persisted in 7 of 11 cases (64%) when anti-TNF treatment
resumed. These relapses occurred despite switching to another
anti-TNF agent. Importantly, no relapses were seen upon dis-
continuation of anti-TNF treatment, which suggests that para-
doxical psoriasis does not represent de novo psoriasis. The
clinical presentation showed great variations reminiscent of
classical psoriasis in its clinical forms (plaque-type, guttate, and
pustular) or particular sites of involvement (palmoplantar, scalp,
and skin folds; Fig. 1 and Supplementary Table 1). However, we
also observed some clinical particularities of paradoxical psoriasis,
including a higher frequency of palmoplantar involvement as
compared to classical psoriasis (80 vs. 2–19%37,38) and severe
noncicatricial alopecia, in numerous cases with scalp involvement
(Fig. 1). Histopathology of paradoxical psoriasis showed a large
spectrum with three identiﬁable patterns: an eczematiform
spongiotic pattern; a psoriasis-like pattern (with different
amounts of intraepidermal or subcorneal neutrophilic inﬁltra-
tion); and a lichenoid pattern with focal interface dermatitis
(Fig. 1). However, these patterns were usually overlapping, pre-
sented at variable degrees in most cases, and did not correlate to
the clinical presentations. These ﬁndings suggest that paradoxical
psoriasis is a transient side effect induced by TNF blockade
independent of treatment type (class effect) with diverse clinical
and histological presentations resembling psoriasis.
High IFN expression and pDC numbers in paradoxical psor-
iasis. We analyzed mRNA expression levels of selected innate
cytokines involved in the pathogenesis of psoriasis to identify
expression patterns unique to paradoxical psoriasis. We observed
no signiﬁcant difference in the expression levels of TNF, IL23A,
IL12A, IL36G, IL8 (CXCL8), IL6, and IL1B when comparing skin
lesions from paradoxical psoriasis with classical psoriasis
(Fig. 2a). In contrast, type I IFNs IFNA2 and IFNB1 expression
was greatly increased in paradoxical psoriasis relative to chronic
plaque psoriasis (Fig. 2a). Importantly, high levels of type I IFN
expression were observed in all samples, despite the variability in
clinical and histological presentation. Thus, uniform high levels of
type I IFN expression in lesional skin characterize anti-TNF-
induced paradoxical psoriasis. Interestingly, adaptive T-cell-
derived cytokines IL17A, IL17F, IL17C, IL26, IFNG, IL4, and
IL10 show comparable levels in skin biopsies from paradoxical
and classical psoriasis (Fig. 2b). However, we found signiﬁcantly
increased IL22 expression in paradoxical psoriasis, which corre-
lated signiﬁcantly with the increased type I IFN expression
(IFNA2 r = 0.567, p< 0.005; IFNB1 r = 0.474, p = 0.017; calculated
by Spearman’s rank-correlation).
Type I IFNs are preferentially expressed by pDCs, or natural
type I IFN-producing cells. They can produce 50- to 100-fold
more type I IFNs than any other cell type. We therefore
investigated whether pDCs are present in paradoxical psoriasis
skin lesions by staining parafﬁn-embedded sections with CD123
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(IL3RA). CD123+ lymphoid cells in skin represent bona-ﬁde
pDCs35, as demonstrated by co-staining with BDCA2 (CLEC4C)
in selected cryo-samples of paradoxical psoriasis (Fig. 3b). pDCs
were absent in normal skin from healthy volunteers. However,
conﬁrming previous studies39, we found large numbers of pDCs
in paradoxical psoriasis skin lesions (Fig. 3a). This increase was
signiﬁcantly greater than the number of pDCs found in classical
plaque psoriasis (Fig. 3c). Expression of both IFNA2 (Fig. 3d) and
IFNB1 (Supplementary Figure 1) signiﬁcantly correlated with
pDC quantity, suggesting that they represent the principal source
of type I IFN. Notably, pDC accumulation coincides with elevated
type I IFN expression at a uniform rate regardless of the clinical
or histological phenotype in paradoxical psoriasis.
Anti-TNF enhances IFN by inhibiting pDC maturation. Given
the increased IFNA2 expression in anti-TNF-induced paradoxical
psoriasis, we investigated whether TNF blockade would enhance
IFN-α production by pDCs directly. As LL37 complexed with
DNA has been shown to activate pDCs in psoriasis40,41, and
because CAMP mRNA expression (corresponding to LL37) in
paradoxical psoriasis was comparable to psoriasis (Supplementary
Figure 2), we used LL37/DNA complexes as stimulus to activate
enriched human peripheral blood pDCs in the presence or
absence of anti-TNF antibodies. TNF blockade signiﬁcantly
enhanced IFN-α production by stimulated pDCs measured 48 h
after stimulation (Fig. 3e, f). This was direct effect of TNF
blockade and not mediated by Fc-receptors as shown by a similar
IFN-α increase when using certolizumab, a Fc-free Fab-fragment
of a monoclonal antibody, but not an irrelevant human IgG
antibody (Supplementary Figure 3a, b). Furthermore, addition of
recombinant TNF to the culture strongly suppressed IFN-α
production by activated pDCs (Fig. 3f) indicating that TNF
controls IFN-α production by pDCs. To gain further insights into
the mechanisms by which TNF controls IFN-α production, we
performed time course analyses of cytokine expression in
Patient 1
Patient 2
Patient 3
a
b
c
Fig. 1 Clinical and histological presentation of paradoxical psoriasis. a–c Photographs of cutaneous lesions and corresponding histopathology of three
individual patients presenting paradoxical psoriasis. a Patient 1 with small erythemato-squamous plaques disseminated over the entire body resembling
guttate psoriasis and palmoplantar psoriasis-like lesions. Histology with a classical psoriasis pattern with acanthosis, papillomatosis, parakeratosis, and loss
of the granular layer, but with spongiosis. b Patient 2 with partially crusted, eczematiform lesions on her legs and trunk, palmoplantar psoriasis-like lesions,
and severe scalp involvement. Histology with acanthosis, papillomatosis, also in addition to spongiosis and minimal interface dermatitis. c Patient 3 with
small erythematous plaques and pustules. Noncicatricial alopecia on the site of scalp involvement. Histology with acanthosis, papillomatosis, and
spongiosis. Clinical signs and histopathology of the patients shown are representative of the patient population in this study
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activated pDCs. IFNA2 expression occurred early, peaking at 24
h, whereas TNF expression increased at later time points (48 and
72 h after stimulation) and coincided with the decrease of IFNA2
expression (Fig. 3g). Anti-TNF antibodies did not affect early
IFNA2 expression but markedly increased its levels at 48 and 72
h, indicating that TNF blockade prolongs the ability of pDC to
produce type I IFNs (Fig. 3h and Supplementary Figure 4).
Moreover, addition of recombinant TNF to the culture shortened
IFNA2 expression by pDCs (Fig. 3h). Together these data show
that IFN-α precedes TNF expression and suggest that TNF
replaces IFN-α by inhibiting its expression. Because TNF drives
pDC differentiation into mature DCs, which lose their ability to
produce IFN-α42, we hypothesized that anti-TNF would prolong
type I IFN production of activated pDC by inhibiting their
maturation. Indeed, anti-TNF signiﬁcantly decreased maturation
of pDCs as shown by reduced surface expression of HLA-DR
(CD74) 48 h after activation (Suppl Figure 5a, b). Anti-TNFs also
reduced expression of co-stimulatory molecules CD80 and CD86,
as well as maturation marker CD83, on activated pDCs (Sup-
plementary Figure 5c–g). Addition of recombinant TNF, which
suppressed IFN-α production by pDCs, strongly upregulated
expression of CD80, CD86, and CD83 (Supplementary
Figure 5c–g). These data suggest that TNF controls the duration
of IFN-α production by promoting differentiation of pDCs into
mature DCs. Consequently, TNF blockade inhibits pDC
maturation and prolongs their ability to produce IFN-α, pro-
viding an explanation for high levels of type I IFN in anti-TNF-
induced paradoxical psoriasis.
Anti-TNF increases IFN and pDC numbers in the skin. Next,
we studied whether anti-TNFs are sufﬁcient to increase type I IFN
production in vivo utilizing a skin injury mouse model. In this
mouse model, repetitive tape stripping leads to a short-lived pDC
inﬁltration into injured skin, peaking at 24 h and declining at 48 h
(Fig. 4a)43. Anti-TNF treatment promoted signiﬁcant increased
and sustained pDC inﬁltration (Fig. 4a, b), which paralleled
prolonged type I IFN expression (Fig. 4c). Importantly, pDC
depletion largely abrogated this type I IFN expression, which
conﬁrmed in vivo that pDCs are the principal source of type I
IFNs following TNF blockade (Supplementary Figure 6). Similar
to the human in vitro data, TNF blockade in vivo signiﬁcantly
inhibited pDC maturation as shown by a decreased expression of
Cd80 and Cd86 (Fig. 4d). Interestingly, blocking type I IFN sig-
naling by an anti-type I IFN-receptor (anti-IFNAR) antibody
signiﬁcantly reduced the numbers of pDCs inﬁltrating injured
skin (Fig. 4e). As CXCR3 ligands CXCL9, CXCL10, and CXCL11
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Fig. 2 Increased type I interferon in skin lesions of paradoxical psoriasis. a mRNA expression analysis of pro-inﬂammatory cytokines TNF, IL6, IFNA2, IFNB1,
IL36G, IL12A, IL23A, CXCL8, and IL1B relative to GAPDH in skin lesions of paradoxical psoriasis compared to classical plaque psoriasis. b mRNA expression
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compared to classical plaque psoriasis. Dots represent individual patient and horizontal bar denotes the median value. Data shown as mRNA expression
level relative to mean expression in classical psoriasis (mean value for classical psoriasis was set at 1). Statistical analysis was performed with unpaired
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are induced by type I IFNs and mediate pDC migration into the
skin44,45, we analyzed their expression in our mouse model.
Indeed, we found a signiﬁcant, type I IFN-dependent over-
expression of Cxcl10 and Cxcl11 in the skin of anti-TNF treated
mice at 24, 48, and 72 h, as anti-IFNAR treatment completely
abrogated their expression (Supplementary Figure 7). These data
show that type I IFN production sustains skin inﬁltration of pDCs
and suggest an ampliﬁcation loop in which type I IFN produced
by pDC promotes additional pDC inﬁltration into the skin. These
data demonstrate that blocking TNF decreases pDC maturation
and enhances type I IFN production by pDCs to amplify their
skin inﬁltration.
Anti-TNF promotes paradoxical psoriasis via IFN. Transient
type I IFN production by pDCs promotes wound healing43,
whereas sustained expression may initiate classical psoriasis
development35,46. Because anti-TNF treatment in wild-type mice
increases pDC accumulation and type I IFN production in the
skin, we determined whether it also induced a psoriasis-like
phenotype. Indeed, 6–7 days after tape stripping, the epidermis of
anti-TNF treated mice showed typical hallmarks of psoriasis,
including acanthosis, parakeratosis, and a focal loss of the gran-
ular layer. In addition, we observed basal and suprabasal Ki67
expression indicative of keratinocyte hyperproliferation and
involucrin expression throughout the entire epidermis suggesting
abnormal keratinocyte differentiation (Fig. 5a–d). In contrast, the
epidermis of control mice was similar to untreated skin showing
minimal Ki67-positive keratinocytes and involucrin expression
within the upper epidermal layers (Fig. 5a–d). We then treated
mice with anti-IFNAR antibodies to determine if enhanced type I
IFN induced the psoriatic phenotype. Inhibition of type I IFN
signaling decreased the anti-TNF-induced psoriatic phenotype to
levels indistinguishable from control mice (Fig. 5e, f). Together,
these data indicate that anti-TNF induces a psoriatic phenotype
through enhanced and sustained type I IFN production by pDCs.
These data provide a mechanism that underlies paradoxical
psoriasis.
Development of paradoxical psoriasis is T-cell-independent.
Type I IFN production by pDCs triggers classical psoriasis35
through activation of cDCs and expansion of autoimmune T cells.
These pathogenic T cells are direct triggers of epidermal hyper-
proliferation and their persistence in the skin and circulation of
psoriasis patients are responsible for chronicity and the recurrent
disease course19–21. Because paradoxical psoriasis does not
represent true psoriasis as it never relapses upon cessation of anti-
TNF (Supplementary Table 1), we next asked whether T cells play
a role in paradoxical psoriasis. We depleted conventional T cells
in our paradoxical psoriasis mouse model using anti-TCR-beta
antibody administration. T-cell-depleted mice treated with anti-
TNF developed a psoriasis-like phenotype with increased acan-
thosis that was similar to non-depleted control mice treated with
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Fig. 3 Plasmacytoid dendritic cell (pDC)-derived type I interferon controlled by TNF. a Representative immunohistochemical CD123 (IL3RA)-staining of
skin from a patient with paradoxical psoriasis. b Representative confocal laser scanning microscopy of paradoxical psoriasis stained for BDCA2 (CLEC4C)
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of numbers of CD123-positive pDCs with gene expression of IFNA2. e IFN-α produced by pDCs enriched from peripheral blood mononuclear cells of
healthy volunteers 48 h after stimulation with DNA/LL37 complexes with or without addition of anti-TNF antibodies. f Relative amount of IFN-α produced
by pDCs from healthy volunteers at 48 h, unstimulated or upon stimulation with DNA-LL37 complexes with or without anti-TNF antibodies, with or without
addition of TNF. g Relative IFNA2 and TNF mRNA expression by pDCs isolated from healthy volunteers, stimulated with DNA/LL37, and kept in culture for
6, 24, 48, or 72 h, respectively. f Relative IFNA2 mRNA expression by pDCs from healthy volunteers 6, 24, 48, and 72 h upon stimulation with DNA/LL37
complexes either with anti-TNF antibodies or addition of TNF. Dots represent individual patient/healthy donor (c, d) and horizontal bar denotes the mean
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shown as mean± SD of six independent experiments with blood from six healthy volunteers (for DNA/LL37 + anti-TNF + TNF; n= 3). Data in g and h
depicts one representative of four independent experiments with cells from four different healthy individuals. Statistical analysis was performed in c with
unpaired Student’s t-test and in e and f with paired Student’s t-test, in d the Spearman’s rank-correlation coefﬁcient was calculated
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anti-TNF (Fig. 6a, b). Because unconventional T cells such as γ/δ-
T cells have been implicated in the development of psoriasiform
skin inﬂammation in mouse models47, we treated Rag2−/− mice,
which are deﬁcient of both conventional α/β-T cells and γ/δ-
T cells, with anti-TNF. Similar to wild-type mice, anti-TNF-
treated Rag2−/− mice developed a psoriatic phenotype with sig-
niﬁcantly increased epidermal thickness (Fig. 6a, c). These data
indicate that neither conventional T cells nor γ/δ-T cells are
required for the type I IFN-driven keratinocyte hyperprolifera-
tion. To investigate the role of T cells in human paradoxical
psoriasis, we quantiﬁed CD8+ T cells inﬁltrating the epidermis,
which represent the pathogenic T-cell subpopulation in psor-
iasis28,36. Compared to the large numbers of CD8 T cells present
in the epidermis of classical psoriasis (n = 11), a signiﬁcantly
lower number of CD8+ T cells was present in the epidermis of
paradoxical psoriasis (n = 16; Fig. 6d–f). CD8+ T cells were
completely absent in normal skin of healthy donors (n = 5).
Because mature cDCs in psoriatic skin represent the key stimu-
lators of pathogenic CD8+ T cells to migrate into the epidermis,
we next quantiﬁed mature cDCs in skin samples using the
maturation marker LAMP3. We found a signiﬁcantly increased
number of LAMP3+ cDCs in the skin of classical psoriasis as
compared to skin from healthy donors (Fig. 6g). In contrast, there
were signiﬁcantly fewer LAMP3+ cDCs in paradoxical psoriasis
suggesting a lack of cDC maturation despite the increase type I
IFN expression (Fig. 6g–i). Taken together, these data suggest that
paradoxical psoriasis represents an overactive type I IFN-driven
innate inﬂammation that does not lead to cDC maturation with
consequent T-cell-mediated autoimmune response as in classical
psoriasis.
Discussion
This study identiﬁes the pathophysiological mechanism under-
lying anti-TNF-induced paradoxical psoriasis. By comparing skin
lesions of paradoxical psoriasis with classical psoriasis, we found a
selective and uniform increase of type I IFN expression along
with a marked dermal accumulation of pDCs. Using in vitro and
in vivo models, we then demonstrated that anti-TNFs directly
prolong the ability of pDCs to produce type I IFN. The resulting
overexpression of type I IFNs is sufﬁcient to drive the develop-
ment of the psoriatic skin phenotype observed in paradoxical
psoriasis, which, in contrast to classical psoriasis, is independent
of T cells.
A link between anti-TNFs and increased type I IFN expression
has been suggested by previous ﬁndings that anti-TNF therapy
induces a type I IFN signature in blood of juvenile arthritis
patients48 and can exacerbate lupus, a well-known type I IFN-
driven autoimmune disease49,50. Using a combination of in vitro
and in vivo studies, we now unravel the mechanism by which this
occurs: TNF temporally controls and limits type I IFN expression
by pDCs, and this effect can be reversed by anti-TNFs. Upon
stimulation of pDCs, type I IFN production occurs ﬁrst and is
subsequently relayed by TNF production, which drives pDC
maturation into DCs that lose the ability to produce type I
IFNs51. Therefore, by promoting pDC maturation, TNF directly
controls and limits the duration of type I IFN production by
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pDCs. On the other hand, blocking of TNF activity by anti-TNFs
decreases pDC maturation and thereby prolongs the ability of
pDC to produce type I IFN. Together our ﬁndings suggest a yin-
yang model in which there is a temporal equilibrium between
early type I IFN and late TNF expression48 that is shifted by TNF
blockade toward a prolonged and excessive type I IFN response.
Our study shows that the type I IFN overproduction in para-
doxical psoriasis is required for the development of a psoriatic
skin phenotype. This ﬁnding raises questions about the differ-
ences between paradoxical psoriasis and classical psoriasis, which
is also driven by an early type I IFN production by pDCs35. Our
data show that unlike classical psoriasis, which is a T-cell-
mediated autoimmune disease, development of paradoxical
psoriasis is independent of T cells. Therefore, both paradoxical
psoriasis and classical psoriasis are triggered by pDCs and type I
IFN, but only classical psoriasis develops into a T-cell-mediated
relapsing autoimmune disease. In contrast, paradoxical psoriasis
fails to elicit an adaptive immune response and remains ﬁxed in
an ongoing pDC-driven innate immune response. These ﬁndings
explain why there is no disease memory in paradoxical psoriasis
while classical psoriasis is characterized by T-cell-mediated
recurrent ﬂare-ups. There are two possible explanations for the
lack of T-cell autoimmunity in paradoxical psoriasis. In classical
psoriasis, the type I IFN response is rapidly replaced by increasing
levels of TNF, which is critical for the maturation of cDCs that
stimulate T cells46. In the context of paradoxical psoriasis, TNF
blockade inhibits the induction of mature cDC and subsequent T-
cell activation, while magnifying type I IFN-driven innate
inﬂammation. Another possibility is that paradoxical psoriasis
patients lack genetic risk variants that drive and regulate T-cell
autoimmunity. In fact, variants involving T-cell activation and
Th17 differentiation, including IL23A, IL23R, IL12B, HLA-Cw6,
RUNX3, STAT3, and TRAF3IP2 genes have been identiﬁed in
classical psoriasis52,53.
The mechanisms by which type I IFNs promote the psoriatic
skin phenotype are currently unclear. Type I IFN itself does not
induce keratinocyte proliferation nor is it responsible for the
altered differentiation54. Most likely, type I IFN activates immune
cells releasing cytokines that drive the development of a psoriatic
phenotype. One possible link between type I IFN and keratino-
cyte hyperproliferation is IL22, which induces epidermal remo-
deling by promoting proliferation of keratinocytes55,56. Indeed,
type I IFN drives IL22 expression, as absence of type I IFN sig-
naling completely abrogates induction of IL22 expression in
skin43. Accordingly, IL22 is selectively upregulated in paradoxical
psoriasis and signiﬁcantly correlates with type I IFN expression.
The cellular source of IL22 remains unclear. Because T cells do
not play a role in paradoxical psoriasis, potential candidates
include innate lymphoid cells (ILC3), natural killer cells57, mast
cells58, and neutrophils59, which have all been reported to express
IL22.
In addition to increased type I IFN expression, higher numbers
of skin pDCs are observed in paradoxical psoriasis as compared
to classical psoriasis. The increased pDC numbers is not a direct
anti-TNF effect, but rather dependent on the type I IFN over-
expression induced by TNF blockade. Although the exact
mechanisms by which type I IFN drives pDC inﬁltration in
paradoxical psoriasis remains to be elucidated, CXCR3 ligands
induced by type I IFNs may prolong the recruitment of pDCs into
the skin in a self-amplifying loop44.
Our study also identiﬁes a new mouse model for the induction
of a psoriasiform skin phenotype with acanthosis, basal kerati-
nocyte hyperproliferation, and altered epidermal differentiation.
This model displays the following three key features of human
paradoxical psoriasis, which are clearly distinct from classical
psoriasis. First, the psoriatic phenotype in this model is induced
and not blocked by anti-TNFs; second, like in paradoxical psor-
iasis, the phenotype in this model is T-cell-independent, whereas
classical psoriasis is a T-cell-mediated disease; and ﬁnally, the
model shows sustained type I IFN expression, which is in line
with the persistent type I IFN expression in the skin of para-
doxical psoriasis but not classical psoriasis. An intriguing ques-
tion is why anti-TNF is able to induce a psoriatic phenotype in
wild-type mice and enhance type I IFN production by pDCs from
blood of healthy donors, but only 2–5% of anti-TNF-treated
patients develop paradoxical psoriasis. The future identiﬁcation of
speciﬁc genetic variants potentially involving pDC activation and/
or type I IFN signaling may provide an explanation for an
increased susceptibility of these individuals to develop para-
doxical psoriasis in the context of anti-TNF treatment.
In conclusion, this study identiﬁes the relevance of the tem-
poral equilibrium of TNF and type I IFN (TNF-IFN yin-yang) in
the pathogenesis of paradoxical psoriasis. While TNF controls
type I IFN under steady-state conditions, anti-TNF treatment
may tip the balance toward type I IFN ultimately driving the
psoriatic phenotype in paradoxical psoriasis. In contrast to clas-
sical psoriasis, paradoxical psoriasis fails to turn into a T-cell-
mediated autoimmune disease with a relapsing course but
remains a drug-related side effect in which inﬂammation perpe-
tuates in self-amplifying innate immune response. These ﬁndings
provide the basis for the design of new strategies targeting pDCs
and type I IFN for the treatment and prevention of paradoxical
psoriasis.
Methods
Clinical data. This study was performed in accordance with the guidelines of the
Declaration of Helsinki and was approved by the local ethics committee (Ethics
Committee Vaud, swissethics). Clinical data of 25 patients with paradoxical
psoriasis were collected at the Department of Dermatology, University Hospital
CHUV, Lausanne (n = 16) and the Department of Dermatology, University Hos-
pital of Zurich (n = 9) between 2011 and 2013. Paradoxical psoriasis was deﬁned as
newly appearing psoriasiform skin lesions under anti-TNF therapy despite
response to treatment.
Skin biopsies. Skin biopsies were taken from patients with paradoxical psoriasis or
untreated classical plaque psoriasis after written informed consent was obtained.
Human samples were ﬁxed using 4% paraformaldehyde for immunohistochemistry
(samples available from all 25 patients) or snap-frozen and stored at −80 °C for
reverse transcription-PCR (RT-PCR) (cryomaterial available from 14 out of the 25
patients). Parafﬁn-embedded skin sections were deparafﬁnized, stained with anti-
CD123 (BD Pharmingen), anti-LAMP3 (Sino Biological, 10527-RP02-50), or anti-
CD8 (DAKO, C8/144B), and visualized using standard horseradish peroxidase
technique. Frozen skin sections were ﬁxed with 4% paraformaldehyde and stained
for BDCA2 (anti-BDCA2-biotin, clone AC144, Miltenyi, plus streptavidin-
Alexa488) and for CD123 (anti-CD123–phycoerythrin, clone 7G3, BD Bios-
ciences). For quantitative RT-PCR, cDNA was synthesized using Superscript II
reverse transcriptase (Invitrogen) and relative Gene expression was quantiﬁed
using speciﬁc Taqman probes (Life Technologies, Supplementary Table 2) and
expressed as 2−ΔΔCT using GAPDH as endogenous control.
For immunoﬂuorescence analyses of mouse tissue, cryopreserved skin samples
were stained with anti-involucrin (Covance, PRB-140C-200, 1/400) or anti-Ki-67
(eBiosciences, SolA15, 1/1000) followed by labeled secondary antibody. For ﬂow
cytometry analysis, mouse skin was digested with Dispase (Sigma-Aldrich) and
collagenase (Invitrogen), and stained with anti-B220 FITC (BD Pharmingen, RA3-
6B2, 1/400), anti-CD45 PerCp-Cy5.5 (BD Pharmingen, 30-F11, 1/400), anti-CD11c
PE (eBioscience, N418, 1/800), and anti-PDCA1 APC (Biolegend, 927, 1/400), anti-
CD80 PE (BD Pharmingen, 16-10A1, 1/800), or anti-CD86 PE (BD Pharmingen,
GL1, 1/800). For ﬂow cytometry analyses of human pDCs, antibodies used include
anti-CD123 APC (Biolegend, 6H6, 1/400), anti-BDCA2 PE (Miltenyi, AC144, 1/
400), anti-BDCA4 APC (Miltenyi, REA-380, 1/400), anti-CD80 PE (BD
Pharmingen, 16-10A1, 1/800), anti-CD83 FITC (eBioscience, HB15e, 1/400), and
anti-HLA-DR (BD Pharmingen, G46-6, 1/400). Assessors were blinded for all
histological quantiﬁcations.
Cell culture. pDCs were puriﬁed from peripheral blood mononuclear cells
obtained from blood buffy coats of healthy donors by Ficoll separation followed by
enrichment using a CD304 Microbeads kit (Miltenyi Biotech). pDCs were cultured
in RPMI 1640 + GlutaMAX (Gibco) supplemented with 10% fetal bovine serum
and 1% penicillin/streptomycin and stimulated with 10 µg/ml human DNA
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(Biochain) complexed with 50 µg/ml LL37 (Proteogenix) with or without 1 µg/ml
anti-TNF antibodies (Adalimumab, Humira), or 100ng/ml recombinant human
TNF (RnD). After 48 h of culture, IFN-α was measured in cell-free supernatants by
enzyme-linked immunosorbent assay (Mabtech).
Mouse models. All animal experiments were performed according to institutional
guidelines and Swiss federal and cantonal laws on animal protection. Ethical
approval was obtained for all described experimentation according to regulations
by the Federal Food Safety and Veterinary Ofﬁce. Animals were maintained and
bred in pathogen-free facilities. Age- (8–10 weeks old) and sex-matched mice were
used for all experiments. Female wild-type Balb/c mice were purchased from
Jackson Laboratory, hBDCA2-DTR (hCLEC4C-DTR) mice were bred at our facility.
Skin injury was performed as previously described43. Brieﬂy, mice were anesthe-
tized and their lower backs shaved using clippers, and then depilated using the
commercially available Veet cream. After cream removal with a paper tissue, 10
gentle strokes of commercially available tape (Scotch, 3M) were applied to the
lower back. Dosage of antibodies applied was deduced from therapeutic use in
humans and injected intraperitoneally as follows: 1500 µg of anti-TNF (inﬂiximab,
Remicade) at days −1 and 0; 200 µg of anti-TCRβ (BioXCell, h57-597) at days −2, 0,
2, and 4; and 250 µg of anti-IFNAR (BioXCell, MAR1-5A3) at days −1, 0, 1, and 3.
We used Remicade because it was previously shown to efﬁciently block both
human and mouse TNF60. However, as a positive control, we used a mouse-speciﬁc
anti-TNF antibody (Supplementary Figure 8). As a negative control, we used an
irrelevant human IgG antibody (Supplementary Figure 8). Effective blockade of
type I IFN signaling by the anti-IFNAR antibody is demonstrated by the absence of
type I IFN-response genes at day 7 after mechanical injury (Supplementary Fig-
ure 9). For pDC-depletion experiments, 120 ng of diphtheria toxin was injected
intraperitoneally into hBDCA2-DTR mice at day −1. At indicated time points,
injured skin was excised for histology, ﬂow cytometry, and gene expression
analysis.
Statistics. Unpaired non-parametric Mann–Whitney U-test was used for analysis
of human gene expression and histological analysis. To investigate an association
between pDCs and type I IFN gene expression, the Spearman’s rank-correlation
coefﬁcient was calculated. For preclinical mouse data, Student’s t-test was used to
perform statistical analyses. All testing was two-sided, and a p-value of <0.05 was
considered to indicate statistical signiﬁcance. All analyses were performed with
GraphPad Prism 6.0.
Data availability. All relevant data are available from the corresponding authors
upon reasonable request.
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